-
Regulatory November 7, 2024Vivesto signs Apealea option agreement with Zhida Pharmaceutical
-
Non Regulatory July 1, 2024Vivesto receives positive Cantrixil preclinical efficacy data
-
Regulatory May 23, 2024Report from Annual General Meeting in Vivesto AB
Interim Report Q2 2024
Vivesto published its Q2 report for 2024 on August 22, 2024, at 08.00 am CEST.
(in Swedish)